Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68) Financial Results: Ipca Laboratories
IPCA Laboratories Ltd
-(IPCALAB)
XNSE:IPCALAB, XBOM:524494
IPCA Laboratories Q4FY23; 42% Fall in Profits
IPCA Laboratories Ltd.’s revenue in Q4FY23 rose 17% to ₹ 1,511 crores. Consolidated Profit After Tax came at ₹ 81 crores in
Earnings Summary Of Ipca Laboratories Industries Limited For Q4 FY23
Ipca Laboratories Limited is a leading pharmaceutical company headquartered in Mumbai, India. With over 75 years of experience, the company specializes in
Earnings Summary Of IPCA Laboratories Limited For Q3 FY23
Ipca Laboratories (NSE: IPCALAB) is a leading pharmaceutical company in India that produces and markets a broad range of prescription and non-prescription
IPCA Laboratories Ltd Q3 FY23 Earnings Conference Call Insights
Key highlights from IPCA Laboratories Ltd (IPCALAB) Q3 FY23 Earnings Concall Q&A Highlights: [00:11:51] Kunal Dhamesha of Macquarie asked if IPCALAB is
IPCA Laboratories Ltd (IPCALAB) Q3 FY23 Earnings Concall Transcript
IPCA Laboratories Ltd (NSE:IPCALAB) Q3 FY23 Earnings Concall dated Feb. 16, 2023. Corporate Participants: Ajit Kumar Jain -- Joint Managing Director Harish Kamath -- Corporate Counsel
Ipca Laboratories Limited Q3 FY23; Revenue Increased To ₹1,546 Crore
Ipca Laboratories Limited (NSE: IPCALAB) reported Revenue from Operations for Q3 FY23 of ₹1,546 Crore up from ₹1,430.47 Crore year on year,